PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 12, 2026Journal of Ophthalmology0 citationsOpen Access

Impact of Comorbid Hypertension and Diabetes on Anti‐VEGF Treatment Outcomes in Macular Edema

View Full Paper
WLWeilin LuSYShanshan YangCZCong Zheng

Key Points

  • The study aims to assess how comorbid hypertension and diabetes affect outcomes from anti-VEGF treatment in macular edema patients.
  • Conducted a longitudinal observational study involving 89 patients with macular edema receiving anti-VEGF treatment.
  • Compared changes in visual acuity and macular edema severity across four patient groups at three time points.
  • Employed regression analysis to examine the correlation between treatment frequency and visual improvement.
  • Significant improvements in best-corrected visual acuity (BCVA) and central macular thickness (CMT) were observed after anti-VEGF treatment.
  • The group without comorbidities showed the highest improvements: BCVA increased from 0.20 to 0.40 logMAR, and CMT decreased from 600 μm to 200 μm.
  • Patients with hypertension and/or diabetes had reduced treatment responses, with multifactorial regression indicating these conditions negatively predict BCVA and CMT improvements.

Abstract

Objective This study evaluated the effects of intravitreal injection of antivascular endothelial growth factor (VEGF) treatment on visual acuity and macular edema severity in patients with comorbid hypertension and diabetes macular edema in China. Method A longitudinal observational study, involving a total of 89 cases with macular edema who received anti‐VEGF injection treatment, compared the changes in visual acuity and macular edema severity among four groups of patients at three different time points. Additionally, through regression analysis, it explored the changes in best‐corrected visual acuity (BCVA) and central macular thickness (CMT) in patients with hypertension and diabetes after receiving different numbers of anti‐VEGF treatments, as well as the relationship between the number of injections and visual improvement and edema reduction. Results Significant improvements in BCVA and CMT were observed following anti‐VEGF treatment, most notably after the first injection. The group without comorbidities demonstrated the greatest improvements, with BCVA improving from 0.20 to 0.40 logMAR and CMT decreasing from approximately 600 μm to 200 μm. In contrast, patients with hypertension and/or diabetes exhibited attenuated therapeutic responses. Multifactorial regression analysis confirmed that the presence of hypertension and/or diabetes served as an independent negative predictor for both BCVA improvement ( β = 0.12, p = 0.002) and CMT reduction ( β = −149.8, p < 0.001). Furthermore, poorer control of blood pressure and blood glucose levels was associated with diminished anatomical improvement. Conclusion In summary, patients with both hypertension and diabetes face greater challenges in terms of their overall health condition, the rate of vision decline, and the improvement of macular edema. It is recommended to initiate treatment for patients with comorbidities earlier, increase the number of injections, and combine other therapies to enhance the treatment effect. Trial Registration Taizhou Municipal Hospital: LWYJ2025268

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Lu et al. (2026) studied this question.

synapsesocial.com/papers/698d6de45be6419ac0d53287https://doi.org/10.1155/joph/8794635
Ask AI
Helpful
Bookmark
Share
View Full Paper